Neuromyelitis Optica (NMOSD)

Table of Contents

1. What is NMOSD?
2. Antibodies and Subtypes
3. Symptoms and Attacks
4. How NMOSD Differs from MS
5. Diagnosis
6. Acute Attack Treatment
7. Relapse Prevention Therapies
8. MS Therapies to Avoid in NMOSD
9. Prognosis and Long-Term Outlook
10. Research Papers
11. Connections
12. Featured Videos

Back to Table of Contents

What is NMOSD?

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare, severe autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord. It was historically called Devic's disease and was long mistaken for a variant of multiple sclerosis (MS). The discovery of the aquaporin-4 IgG (AQP4-IgG) antibody in 2004 established NMOSD as a distinct condition with its own pathophysiology, biomarkers, and treatment requirements.

NMOSD affects approximately 1–4.4 people per 100,000, with a strong female predominance (roughly 9:1 female-to-male ratio). It can occur at any age but most commonly presents in the fourth decade of life. Unlike MS, NMOSD tends to cause more severe, disabling attacks with less spontaneous recovery — making early diagnosis and aggressive relapse prevention critical.

Back to Table of Contents

Antibodies and Subtypes

NMOSD is defined by antibodies targeting specific proteins on astrocytes and oligodendrocytes in the CNS.

AQP4-IgG Positive NMOSD

• Most common subtype, accounting for approximately 73–80% of NMOSD cases.
• Targets aquaporin-4 (AQP4), a water channel protein highly expressed on astrocyte end-feet that abut the blood-brain barrier.
• AQP4-IgG causes complement-mediated destruction of astrocytes, leading to secondary demyelination and axonal loss.
• Detected by cell-based assay (CBA) using HEK293 cells transfected with AQP4 — the gold-standard test with sensitivity ~73% and specificity ~99%.

MOG-IgG Positive NMOSD (MOGAD)

• Targets myelin oligodendrocyte glycoprotein (MOG), a protein on the outer surface of myelin sheaths.
• Now recognized as a distinct entity called MOG Antibody-Associated Disease (MOGAD), separate from AQP4+ NMOSD.
• More commonly causes optic neuritis (often bilateral and recurrent) and cortical encephalitis; spinal cord lesions are less longitudinally extensive than in AQP4+ disease.
• Prognosis is more favorable than AQP4+ NMOSD — a significant proportion of patients have a monophasic course without relapse.
• Testing should use a live cell-based assay; tissue-based assays give false positives.

Seronegative NMOSD

• Approximately 10–20% of clinically diagnosed NMOSD patients test negative for both AQP4-IgG and MOG-IgG.
• Likely represents a heterogeneous group; additional undiscovered antibodies may be present.
• Diagnosis requires strict clinical and MRI criteria per the 2015 International Panel for NMO Diagnosis (IPND) criteria.

Back to Table of Contents

Symptoms and Attacks

NMOSD attacks are typically severe and leave residual disability. The hallmark attacks involve the optic nerves and spinal cord, though area postrema (vomiting center) and brain attacks also occur.

Optic Neuritis

• Often bilateral (vs. typically unilateral in MS), severe, and associated with significant vision loss.
• Presents with pain behind the eye worsened by eye movement, followed by rapidly progressive visual loss.
• Without treatment, permanent blindness in one or both eyes can result.
• MRI shows longitudinally extensive optic nerve enhancement, often involving the optic chiasm — uncommon in MS.

Longitudinally Extensive Transverse Myelitis (LETM)

• Spinal cord lesions spanning 3 or more vertebral segments on MRI — the defining MRI feature of NMOSD myelitis.
• Causes severe limb weakness or paralysis, sensory loss, and bladder/bowel dysfunction.
• Attacks may leave permanent paraplegia or tetraplegia without rapid treatment.
• Lesions preferentially affect the central gray matter (especially cervical and thoracic cord).

Area Postrema Syndrome

• Intractable hiccups, nausea, and vomiting lasting days — a highly specific feature of NMOSD.
• Caused by lesions in the dorsal medulla/area postrema, which lacks a blood-brain barrier and is highly accessible to AQP4-IgG.
• Often misattributed to gastrointestinal disease, delaying diagnosis.

Other CNS Attacks

• Brainstem syndrome: diplopia, facial numbness, dysphagia, respiratory failure (life-threatening).
• Diencephalic syndrome: narcolepsy-like hypersomnia, hypothermia, syndrome of inappropriate antidiuresis (SIAD).
• Cerebral syndrome: encephalopathy, seizures, cortical blindness (more common in MOGAD).

Back to Table of Contents

How NMOSD Differs from MS

NMOSD is frequently misdiagnosed as MS early in the disease course. Correct differentiation is critical because some MS therapies worsen NMOSD.

• Attack severity: NMOSD attacks are generally more severe and leave greater residual disability than MS attacks. Permanent blindness and paraplegia after a single attack are not rare in NMOSD.
• Optic neuritis pattern: NMOSD optic neuritis is often bilateral, posterior (involving the optic chiasm), and more severe; MS optic neuritis is usually unilateral, anterior, and self-limiting.
• Spinal cord lesions: NMOSD = LETM (≥3 segments, central, T1-hypointense "black holes"); MS = short lesions (1–2 segments), often peripheral/dorsal.
• Brain MRI: Brain lesions occur in NMOSD but are less characteristic — MS shows ovoid periventricular Dawson's finger lesions; NMOSD brain lesions are often in AQP4-rich areas (area postrema, hypothalamus, periaqueductal gray).
• Cerebrospinal fluid: NMOSD CSF often shows pleocytosis with neutrophils during attacks; MS CSF shows oligoclonal bands (present in >95% of MS, only ~20–30% of NMOSD).
• Disease course: Most NMOSD is relapsing (high relapse rate without treatment); MS has progressive forms; true monophasic NMO occurs but is less common in AQP4+ disease.
• Biomarker: AQP4-IgG and MOG-IgG are specific to NMOSD/MOGAD; MS has no definitive serum biomarker.

Back to Table of Contents

Diagnosis

Diagnosis is based on the 2015 IPND criteria, which requires at least one core clinical characteristic plus AQP4-IgG seropositivity (or, if seronegative, additional clinical/MRI criteria).

• Core clinical characteristics: optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy/diencephalic syndrome, symptomatic cerebral syndrome.
• AQP4-IgG serology (cell-based assay): positive result in a single core clinical characteristic is sufficient for diagnosis.
• MOG-IgG serology (live cell-based assay): should be tested in AQP4-IgG-seronegative patients.
• MRI brain and spinal cord: look for LETM, area postrema/dorsal medulla lesions, periaqueductal and hypothalamic lesions.
• MRI orbits with fat suppression: for optic neuritis assessment, especially posterior/chiasmatic involvement.
• CSF analysis: may show neutrophilic or eosinophilic pleocytosis, elevated protein; oligoclonal bands usually absent.
• Visual evoked potentials (VEPs): assess optic nerve function and subclinical involvement.
• Exclude mimics: MS, sarcoidosis, vitamin B12 deficiency, paraneoplastic disorders, SLE/Sjogren's-associated myelitis.

Back to Table of Contents

Acute Attack Treatment

NMOSD attacks are medical emergencies. Early, aggressive treatment is essential to minimize permanent disability.

• High-dose IV methylprednisolone: 1 g/day for 3–5 days is first-line for all acute attacks, started as soon as possible.
• Plasma exchange (PLEX): 5–7 cycles every other day; used for severe attacks not responding to steroids within 5 days, or as first-line co-treatment with severe myelitis or vision loss. Removes circulating AQP4-IgG. Evidence supports PLEX improving outcomes in steroid-refractory attacks (PMID: 25792674).
• Intravenous immunoglobulin (IVIG): sometimes used as an alternative to PLEX when PLEX is unavailable or contraindicated.
• Symptomatic care: Foley catheter for neurogenic bladder, DVT prophylaxis, respiratory monitoring for brainstem attacks, pain management for neuropathic pain.

Back to Table of Contents

Relapse Prevention Therapies

Because each NMOSD relapse carries a high risk of permanent disability, long-term immunosuppression for relapse prevention is started as soon as the diagnosis is confirmed. Four FDA-approved therapies exist for AQP4-IgG positive NMOSD (all approved 2019–2020).

FDA-Approved Therapies (AQP4-IgG+ NMOSD)

• Inebilizumab (Uplizna): Anti-CD19 monoclonal antibody depleting B cells and plasmablasts. FDA approved June 2020. Reduced risk of NMOSD attack by 77% vs placebo in the N-MOmentum trial (PMID: 31987001). IV infusion every 6 months after loading doses.
• Satralizumab (Enspryng): Anti-IL-6 receptor monoclonal antibody. FDA approved August 2020. Reduced relapse risk by 74% in AQP4-IgG+ patients in the SAkuraStar trial (PMID: 31050067). Subcutaneous injection every 4 weeks — only FDA-approved subcutaneous NMOSD therapy.
• Eculizumab (Soliris): Anti-C5 complement inhibitor. FDA approved June 2019. Reduced relapse risk by 94% vs placebo in PREVENT trial (PMID: 31050068). IV infusion every 2 weeks after loading. High cost; meningococcal vaccination required before starting.
• Ravulizumab (Ultomiris): Extended-half-life anti-C5 (same target as eculizumab), FDA approved June 2024 for NMOSD. IV infusion every 8 weeks. Replaces need for bi-weekly eculizumab.

Rituximab (Off-Label, Widely Used)

• Anti-CD20 monoclonal antibody depleting B cells. Not FDA-approved specifically for NMOSD but is the most widely used preventive therapy globally due to cost and extensive experience.
• Reduces annual relapse rate by approximately 75–90% in observational studies. IV infusion every 6 months or guided by CD19/CD27 B-cell counts.
• Often preferred as first-line in resource-limited settings or where cost of newer agents is prohibitive.

Other Immunosuppressants (Older, Less Effective)

• Azathioprine + oral prednisolone: low-cost combination used widely before newer agents; reduces relapses but less effectively than biologic therapies.
• Mycophenolate mofetil: steroid-sparing agent; used where azathioprine is not tolerated.
• Treatment of MOGAD: IVIG or rituximab are commonly used; evidence base is smaller; the approved AQP4+ therapies have not been tested in large MOGAD-specific trials.

Back to Table of Contents

MS Therapies to Avoid in NMOSD

Several disease-modifying therapies (DMTs) effective for MS are contraindicated or potentially harmful in AQP4-IgG+ NMOSD. Prescribing them before ruling out NMOSD can lead to catastrophic relapses.

• Natalizumab (Tysabri): Anti-VLA-4 integrin; case series and a pharmacovigilance study demonstrated high relapse rates and severe attacks in AQP4+ patients (PMID: 22752773). Avoid in NMOSD.
• Fingolimod (Gilenya): Sphingosine-1-phosphate receptor modulator; multiple case reports of severe relapses and rebound in NMOSD patients. Avoid in NMOSD.
• Interferon-beta (IFN-β): First-line for MS; ineffective and possibly harmful in NMOSD — associated with increased relapse frequency in AQP4+ patients.
• Alemtuzumab (Lemtrada): High-efficacy MS therapy; case reports of new-onset or worsening NMOSD after treatment. Use with extreme caution; contraindicated by most guidelines.
• Glatiramer acetate: Generally considered ineffective (though likely not worsening) in NMOSD.
• Ocrelizumab (Ocrevus) / ofatumumab: Anti-CD20; theoretically similar to rituximab but evidence in NMOSD is limited; may be used off-label but not formally studied in NMOSD populations.

Back to Table of Contents

Prognosis and Long-Term Outlook

NMOSD prognosis has improved substantially with targeted therapies, but the disease remains a cause of severe disability without adequate treatment.

• Before modern therapies, approximately 50% of patients were legally blind or wheelchair-dependent within 5 years of onset.
• Each relapse carries a ~50% chance of incomplete recovery.
• Mortality: Respiratory failure from cervical myelitis or brainstem attacks is the primary cause of NMOSD-related death. With modern immunosuppression, mortality has declined.
• AQP4-IgG+ NMOSD is almost always relapsing; spontaneous remission is uncommon.
• MOGAD has a better prognosis — up to 30–40% of patients have a monophasic course; those who do relapse typically have less accumulated disability than AQP4+ patients.
• Comorbid autoimmune conditions (SLE, Sjogren's syndrome, myasthenia gravis) are more common in AQP4+ NMOSD patients and should be screened for.
• Neuropathic pain, fatigue, bladder dysfunction, and depression require ongoing symptomatic management regardless of relapse activity.

Back to Table of Contents

Research Papers

Curated PubMed topic searches and direct PMID links on Neuromyelitis Optica Spectrum Disorder. Each link opens a live query or specific paper.

1. Plasma exchange in steroid-refractory NMOSD attacks (PMID 25792674)
2. Inebilizumab N-MOmentum trial in NMOSD (PMID 31987001)
3. Satralizumab SAkuraStar trial AQP4+ NMOSD (PMID 31050067)
4. Eculizumab PREVENT trial NMOSD (PMID 31050068)
5. Natalizumab worsening in NMOSD (PMID 22752773)
6. PubMed: NMOSD AQP4-IgG diagnosis criteria
7. PubMed: 2015 IPND diagnostic criteria for NMOSD
8. PubMed: MOG antibody-associated disease (MOGAD)
9. PubMed: Rituximab NMOSD relapse prevention
10. PubMed: NMOSD longitudinally extensive transverse myelitis
11. PubMed: Area postrema syndrome NMOSD
12. PubMed: NMO vs MS differential diagnosis MRI

Back to Table of Contents

Connections

• Multiple Sclerosis
• Myasthenia Gravis
• Peripheral Neuropathy
• Guillain-Barré Syndrome
• Transverse Myelitis
• ALS
• Cerebellar Ataxia
• Chronic Fatigue Syndrome (ME/CFS)
• Narcolepsy
• Trigeminal Neuralgia
• Vitamin D3
• Vitamin B12
• Magnesium
• Vision Problems
• Fatigue
• Chronic Pain
• Depression
• Charcot-Marie-Tooth Disease

Back to Table of Contents

×

Featured Videos